Recently, SH3YL1 has emerged as a potential biomarker for AKI, particularly in contexts associated with increased oxidative stress, sparking interest in its expression dynamics in bladder cancer patients receiving cisplatin therapy [38]. This evidence concerns the gene SH3YL1 and urinary bladder cancer.